ITBMed Raises $67M To Induce Organ Transplant Tolerance

Swedish biopharma ITBMed has secured $67m to develop siplizumab, its anti-CD2 monoclonal antibody, as an alternative to life-long use of conventional immunosupressants in organ transplant patients.

US dollars

Long-term results of organ transplantation remain unsatisfactory, mainly because of chronic rejection and complications associated with immunosuppressive medications. Swedish biopharma ITBMed AB is developing a humanized anti-CD2 monoclonal antibody, siplizumab (formerly known as MEDI-507), that has shown promise in a Phase II study in HLA-mismatched kidney transplant patients can achieve tolerance of the transplanted organs with the need for lifelong immunosuppression.

ITBMed has raised $67m, led by Pablo Legoretta, the founder and CEO of Royalty Pharma, to further develop the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip